Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Sanofi Eligibility Criteria Questions: 1 - 2

Did the HCT occur ≤ 12 months from start of initial therapy for myeloma?1

Yes

No (HCT occurred > 12 months from start of initial therapy for myeloma)

Did the recipient have associated light chain (AL) amyloidosis?

Yes No

2

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Center: CRID: 

Form 2564 R1.0: Sanofi Eligibility

CIBMTR Form 2564 revision 1.0 last updated Monday, October 02, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 1